Skip to main content
Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden flag Sweden · Delayed Price · Currency is SEK
5.80
+0.01 (0.17%)
Apr 29, 2026, 5:29 PM CET

Egetis Therapeutics AB Revenue

In the year 2025, Egetis Therapeutics AB had annual revenue of 62.40M SEK with 35.36% growth. Egetis Therapeutics AB had revenue of 17.80M in the quarter ending December 31, 2025, with 64.81% growth.

Revenue
62.40M
Revenue Growth
+35.36%
P/S Ratio
36.67
Revenue / Employee
1.49M
Employees
42
Market Cap
2.29B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202562.40M16.30M35.36%
Dec 31, 202446.10M-11.50M-19.97%
Dec 31, 202357.60M35.00M154.87%
Dec 31, 202222.60M-15.60M-40.84%
Dec 31, 202138.20M-2.46M-6.05%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Flerie AB 1.80M
Hansa Biopharma AB 190.49M
Saniona AB 434.40M
Vicore Pharma Holding AB 3.82M
BioInvent International AB 226.50M
Genovis AB (publ.) 129.65M
Xspray Pharma AB 2.47M
Medivir AB 8.51M
Revenue Rankings

Egetis Therapeutics AB News

More News